Menu
- Lisa Colter
Doctors Reattach Boy’s Head After Car Accident Thanks to ‘Amazing’ Surgery
- Lisa Colter
Hadassah Medical Center Researchers Tout ‘Hopeful’ Treatment Results For Myeloma Cancer
- Lisa Colter
Israeli CAR-T cancer treatment could be administered out-patient – first in the world
- Lisa Colter
Jerusalem’s Hadassah medical center named global leader in several fields
- Lisa Colter
Israeli Humanitarian Aid Delegation Departs for Türkiye
‘We’ll do our best to save lives’: IDF rescue delegation arrives in southern Turkey
- Lisa Colter
Prof. Polina Stepensky Explains The CAR (Chimeric Antigen Receptor) T-Cell Therapy.
Hadasit, the Innovation Engine of Hadassah Medical Organization and BIRAD, the Commercialization arm of Bar-Ilan University announced today that they have entered into the research and license agreement with Immix BioPharma, for the development and commercialization of novel tissue specific therapeutics based on anti-BCMA CAR-T cells targeting plasma cell. This technology has been developed as the result of a collaboration between Prof. Polina Stepensky, of Hadassah Medical Center, Jerusalem and Prof. Cyrille J. Cohen, of Bar-Ilan University, Ramat Gan. Dr. Shlomit Kfir-Erenfeld and Dr. Nathalie Asherie, of Hadassah Medical Center, and Ortal Harush, of Bar-Ilan University, also participated in the research.
For more information visit Yahoo! Finance
- Lisa Colter
Long COVID: Hyperbaric Oxygen Therapy Offers Hope for Understanding and Treating Symptoms
Hyperbaric oxygen therapy in a randomized placebo-controlled trial resulted in improved global cognitive function, energy, sleep, and pain interference in long COVID patients.
